The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (11 analysts) rates it buy, with a mean price target of $34.
Cinemark Holdings, Inc.
CNK · the NYSE · USD · Market cap $4.7B · 8,451 employees
Cinemark Holdings, Inc., together with its subsidiaries, engages in the theatrical exhibition business.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price40.80 USD at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.22)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $46.61 to $77.69, base estimate $47.00 (screen dated 2026-11-13).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.22, read 2026-11-13
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Cinemark Holdings, Inc. holds its Accumulation at $40.80. Consolidating, no directional conviction, held for 95 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 95 days |
| Price at the screen | $40.80 |
| Valuation | 16.55 trailing · 14.29 forward price to earnings |
| Values screen | FAIL · score 70.0 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 67.48% | Below 33% | Interest-bearing debt is 67.5% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 10.25% | Below 49% | Money owed to the company is 10.2% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.24% | Below 5% | Only 1.2% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Cinemark Holdings,'s business is in a permissible area, but its interest-bearing debt is about 67% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CNK's ethical verdict changes
Today CNK does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 13% discount to our $47.00 fair value, 23.50% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 13.2% discount to the base estimate.
Third-party analyst targets: 11 covering, consensus Buy. The average target sits +3% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & ProjectionsWhere our models see it going: fair-value estimate $47.00, with a range of $46.61 to $77.69, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsCinema crowds return but the business stays cyclical
Picture a packed Friday night screening after years of empty seats. Cinemark is riding a post-pandemic rebound with revenue up 19 percent and return on equity at 47 percent, yet the forward multiple sits at just 12.4 times earnings and the profit margin remains a thin 5 percent. The market prices the shares well below our fair value of 38 dollars, but the opportunity rating stays at none.
The recovery story is real and the ethical screen clears without issue, yet the lack of a visible moat leaves the firm exposed to whatever Hollywood produces next and whatever consumers choose to spend. Analyst targets cluster around 36 dollars on a buy consensus, which still leaves little margin once the cycle turns.
Movie exhibition is a classic cyclical business, so the low multiple may simply reflect peak earnings rather than a bargain. Currency moves in Latin America and shifting viewer habits add further volatility that a simple valuation gap does not capture.
Analysis, not advice.
| Forward P/E | 14.3xcheap for a company growing this fast |
| Trailing P/E | 16.5xreasonably valued |
| EPS, trailing | 2.44 |
| EPS, forward | 2.83 |
| Revenue growth | +23.5%strong top-line growth |
| Profit margin | 8.1%thin but positive margins |
| Dividend yield | 1.32% |
| Debt to equity | 5.88heavy leverage: higher risk if revenue softens |
| Short interest, float | 0.11% |
| 52-week range | 21.60 - 40.75 |
| Market cap | $4.7B |
| Employees | 8,451 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCNK trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (11 analysts) rates it buy, with a mean price target of $34. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (11 analysts) rates it buy, with a mean price target of $34. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (11 analysts) rates it buy, with a mean price target of $34. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (11 analysts) rates it buy, with a mean price target of $34. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (11 analysts) rates it buy, with a mean price target of $34. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (11 analysts) rates it buy, with a mean price target of $34. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (11 analysts) rates it buy, with a mean price target of $34. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (11 analysts) rates it buy, with a mean price target of $34. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 27% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (11 analysts) rates it buy, with a mean price target of $34.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- AMC's AI Theater Programming: Can Automation Boost EBITDA? Yahoo Finance · 3d ago
- Cinemark Declares Quarterly Cash Dividend of $0.09 Yahoo Finance · 3d ago
- Zacks.com featured highlights include Cinemark, Diamondback Energy and Omnicell Yahoo Finance · 5d ago
- Buy These 3 Stocks with Broker Rating Upgrades for Big Gains Yahoo Finance · 5d ago
- Why Cinemark Stock Is Up Today Yahoo Finance · 6d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-05-01 | Ro Khanna | Democrat | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $26.67 | +25.6% | $0.09 | $1,259 | +25.9% |
| 2 months | $30.27 | +10.6% | $0.09 | $1,109 | +10.9% |
| 3 months | $25.45 | +31.6% | $0.09 | $1,320 | +32.0% |
| 6 months | $24.89 | +34.6% | $0.18 | $1,353 | +35.3% |
| 1 year | $31.10 | +7.7% | $0.35 | $1,088 | +8.8% |
| 2 years | $16.50 | +103.0% | $0.51 | $2,061 | +106.1% |
| 3 years | $18.32 | +82.8% | $0.51 | $1,856 | +85.6% |
| 5 years | $22.45 | +49.2% | $0.51 | $1,515 | +51.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CNK does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.